These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 23919911)
1. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia. Ho S; Gue D; McIntosh K; Bucevska M; Yang M; Jackson S Haemophilia; 2014 Jan; 20(1):39-43. PubMed ID: 23919911 [TBL] [Abstract][Full Text] [Related]
2. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center. Dodd C; Watts RG Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939 [TBL] [Abstract][Full Text] [Related]
3. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Mahdi AJ; Obaji SG; Collins PW Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016 [TBL] [Abstract][Full Text] [Related]
4. Changing paradigm of prophylaxis with longer acting factor concentrates. Carcao M Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284 [TBL] [Abstract][Full Text] [Related]
5. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ; Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844 [TBL] [Abstract][Full Text] [Related]
6. The current status of prophylactic replacement therapy in children and adults with haemophilia. Ljung R; Gretenkort Andersson N Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695 [TBL] [Abstract][Full Text] [Related]
7. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States. Thornburg CD; Carpenter S; Zappa S; Munn J; Leissinger C Haemophilia; 2012 Jul; 18(4):568-74. PubMed ID: 22335526 [TBL] [Abstract][Full Text] [Related]
8. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. Berntorp E Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939 [TBL] [Abstract][Full Text] [Related]
9. Prophylaxis in children with haemophilia - the Polish experience. Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651 [No Abstract] [Full Text] [Related]
10. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Ahnström J; Berntorp E; Lindvall K; Björkman S Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163 [TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578 [TBL] [Abstract][Full Text] [Related]
12. Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B. Jackson SC; Yang M; Minuk L; St-Louis J; Sholzberg M; Card R; Iorio A; Poon MC Haemophilia; 2014 May; 20(3):e199-204. PubMed ID: 24589126 [TBL] [Abstract][Full Text] [Related]
13. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients. Nagel K; Walker I; Decker K; Chan AK; Pai MK Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368 [TBL] [Abstract][Full Text] [Related]
14. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380 [TBL] [Abstract][Full Text] [Related]
15. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845 [TBL] [Abstract][Full Text] [Related]
16. The overall effectiveness of prophylaxis in severe haemophilia. Panicker J; Warrier I; Thomas R; Lusher JM Haemophilia; 2003 May; 9(3):272-8. PubMed ID: 12694517 [TBL] [Abstract][Full Text] [Related]
17. [Haemophilia A and haemophilia B. Are there relevant clinical differences?]. Klamroth R; Orlovic M; Kubicek-Hofman C; Gottstein S Hamostaseologie; 2010 Nov; 30 Suppl 1():S26-7. PubMed ID: 21042678 [TBL] [Abstract][Full Text] [Related]
18. Prophylaxis for severe haemophilia: clinical and economical issues. Fischer K; Van Den Berg M Haemophilia; 2003 Jul; 9(4):376-81. PubMed ID: 12828671 [TBL] [Abstract][Full Text] [Related]
19. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan. Taki M; Shirahata A Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Rusen L; Lamas JL; Oh MS; Chapman M; Fritsch S; Pavlova BG; Wong WY; Abbuehl BE Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]